LIFE SCIENCES & PHARMA
Molecular Intelligence for the science of tomorrow.
In life sciences, we see AI innovation slowing down due to strict regulation and data silos.
From molecule to market without compromising integrity. W69 designs AI architecture for Life Sciences where GxP compliance and scientific precision are at the core.
AI for Life Sciences involves deploying AI for clinical research, drug discovery, regulatory compliance and medical data analysis. W69 AI Consultancy in Amsterdam develops AI architectures that help life sciences organizations innovate faster within strict regulatory frameworks.
AI architecture for the life sciences sector
From drug discovery to regulatory submissions — we build systems that combine scientific precision and speed.
Drug Discovery & R&D Intelligence
AI-accelerated molecular analysis, target identification and lead optimization. From millions of candidates to promising compounds in days.
Clinical Trial Optimization
Intelligent patient recruitment, protocol optimisation and real-world evidence. Shorter lead times with higher success rates.
Regulatory & Compliance AI
Automated dossier compilation, GxP compliance and pharmacovigilance. EU Annex 11 and 21 CFR Part 11 ready.
DNA Helix — Research Pipeline
From discovery to market: AI as the connecting architecture through every phase of the research pipeline.
From scientific audit to scalable innovation
Every engagement follows a proven methodology that takes your R&D processes as a starting point and works towards a GxP-compliant, scalable AI architecture.
Scientific Audit
Inventory of R&D processes, data sources and regulatory requirements. We map your scientific AI maturity.
Knowledge Graph
Building a connected knowledge base with scientific literature, patent data and clinical trial information as the foundation.
AI Pipeline
Implementation of drug discovery tools, trial optimization and compliance automation with full GxP validation.
Scalable Innovation
Continuous improvement with federated learning and real-world evidence. Iterative optimisation based on new scientific insights.
What you need to know about AI in Life Sciences
AI analyses millions of molecular structures and identifies promising candidates in days instead of months. Our models combine literature analysis, target identification and lead optimization to accelerate your R&D pipeline while maintaining scientific rigour.
AI improves patient recruitment through matching with inclusion/exclusion criteria, optimises protocol design based on historical trial data and monitors real-world evidence. This shortens lead times and increases the likelihood of successful outcomes.
GxP-by-Design is our core principle. All systems comply with 21 CFR Part 11, EU Annex 11 and GAMP 5 guidelines. Complete validation documentation, audit trails and electronic signatures are built into every system as standard.
Data sovereignty and privacy are fundamental. We work with federated learning, differential privacy and sovereign architecture so that sensitive patient data and intellectual property remain within your controlled environment. Fully GDPR and HIPAA compliant.
Typical results include 60% faster R&D cycles, 10x faster literature analysis and significant cost reduction in clinical trial management. The ROI manifests in shorter time-to-market, higher success rates and automated compliance reporting.
Ready to accelerate your R&D with AI?
Discuss with our architects how AI-driven drug discovery, clinical trial optimization and GxP compliance can look for your organisation.